- Global Wellness Strategies (GWS) is working with BioMed360, a GWS medical advisor and subsidiary that provides financial, operational, and management assistance during clinical trials
- BioMed360 Solutions Corp. signed a letter of intent for the total acquisition of AVM Biotechnology, a developer of a proprietary formulation of its unique molecule AVM0703
- This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged gamma delta+ Natural Killer T-like immune cells, which could play a significant role in several diseases and conditions
- Global Wellness Strategies (GWS) is down 37.50 per cent, trading at $0.25 per share as of 3:20 p.m. ET
Global Wellness Strategies (GWS) is working with subsidiary BioMed360.
BioMed360 is a GWS medical advisor that provides financial, operational and management assistance during clinical trials.
BioMed360 Solutions Corp. signed a letter of intent for the total acquisition of AVM Biotechnology, a developer of a proprietary formulation of its unique molecule AVM0703. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged gamma delta+ Natural Killer T-like (AVM-NKT) immune cells. These cells have unique immune response properties in comparison to ordinary T-cells and rapidly appear following a single AVM0703 dose. Pre-clinical and early clinical data indicate that these cells could play a significant role in several diseases and conditions.
Meris Kott, CEO of Global Wellness Strategies, commented that immunotherapy causes fewer side effects than other treatments because it targets just the immune system and not all the cells in the body.
“Immunotherapies help to slow, stop and kill cancerous cells, and for some patients, can be safer and more effective than even chemotherapy and radiation. Our mission at Global Wellness has always been to embrace health and wellness, and we look forward to assisting BioMed 360 and AVM Biotechnology with their clinical trials capital needs.”
Global Wellness Strategies Inc. (GWS) is a debt financing company. The company provides a debt financing facility to help companies build their valuation and get to the next level in its financing cycle without giving away equity prematurely in their growth cycle. It is focusing on providing finance to medical cannabis, hemp, and CBD-related, healthcare-related target companies.
Global Wellness Strategies (GWS) is down 37.50 per cent, trading at $0.25 per share as of 3:20 p.m. ET.
